Type 1 regulatory T (Tr1) cells play a pivotal role in restraining human T-cell responses toward environmental allergens and protecting against allergic diseases. Still, the precise molecular cues that underlie their transcriptional and functional specification remain elusive. Here, we show that the cytokine activin-A instructs the generation of CD4 + T cells that express the Tr1-cell-associated molecules IL-10, inducible T-Cell costimulator (ICOS), lymphocyte activation gene 3 protein (LAG-3), and CD49b, and exert strongly suppressive functions toward allergic responses induced by naive and in vivo-primed human T helper 2 cells. Moreover, mechanistic studies reveal that activin-A signaling induces the activation of the transcription factor interferon regulatory factor (IRF4), which, along with the environmental sensor aryl hydrocarbon receptor, forms a multipartite transcriptional complex that binds in IL-10 and ICOS promoter elements and controls gene expression in human CD4 + T cells. In fact, IRF4 silencing abrogates activin-A-driven IL10 and ICOS up-regulation and impairs the suppressive functions of human activin-A-induced Tr1-like (act-A-iTr1) cells. Importantly, using a humanized mouse model of allergic asthma, we demonstrate that adoptive transfer of human act-A-iTr1 cells, both in preventive and therapeutic protocols, confers significant protection against cardinal asthma manifestations, including pulmonary inflammation. Overall, our findings uncover an activin-A-induced IRF4-aryl hydrocarbon receptor (AhR)-dependent transcriptional network, which generates suppressive human Tr1 cells that may be harnessed for the control of allergic diseases.
Type 1 regulatory T (Tr1) cells play a pivotal role in restraining human T-cell responses toward environmental allergens and protecting against allergic diseases. Still, the precise molecular cues that underlie their transcriptional and functional specification remain elusive. Here, we show that the cytokine activin-A instructs the generation of CD4 + T cells that express the Tr1-cell-associated molecules IL-10, inducible T-Cell costimulator (ICOS), lymphocyte activation gene 3 protein (LAG-3), and CD49b, and exert strongly suppressive functions toward allergic responses induced by naive and in vivo-primed human T helper 2 cells. Moreover, mechanistic studies reveal that activin-A signaling induces the activation of the transcription factor interferon regulatory factor (IRF4), which, along with the environmental sensor aryl hydrocarbon receptor, forms a multipartite transcriptional complex that binds in IL-10 and ICOS promoter elements and controls gene expression in human CD4 + T cells. In fact, IRF4 silencing abrogates activin-A-driven IL10 and ICOS up-regulation and impairs the suppressive functions of human activin-A-induced Tr1-like (act-A-iTr1) cells. Importantly, using a humanized mouse model of allergic asthma, we demonstrate that adoptive transfer of human act-A-iTr1 cells, both in preventive and therapeutic protocols, confers significant protection against cardinal asthma manifestations, including pulmonary inflammation. Overall, our findings uncover an activin-A-induced IRF4-aryl hydrocarbon receptor (AhR)-dependent transcriptional network, which generates suppressive human Tr1 cells that may be harnessed for the control of allergic diseases.
cytokines | allergic inflammation | immune regulation | activin-A | human T regulatory cells O veractive T helper 2 (Th2) cell-driven responses against inhaled allergens contribute to the development of airway inflammation and airway hyperresponsiveness (AHR), and are associated with allergic asthma, a rising health care problem worldwide (1) . Regulatory T (Treg) cells and, specifically, IL-10-producing type 1 Treg (Tr1) cells exert crucial nonredundant functions in restraining exuberant Th2 responses and maintaining tolerance in mouse models of experimental asthma (2) (3) (4) (5) . Moreover, in humans, the balance between allergen-specific Tr1 and Th2 cells is considered decisive for the outcome of allergic responses (6) . In fact, the tolerogenic effects of allergen-specific immunotherapies are associated with the generation of Tr1 cells (7) . Hence, the identification of factors that can induce and/or expand human Tr1 cells represents an attractive therapeutic approach for the control of allergic responses and linked asthmatic disease.
Despite recent advances in deciphering the human Tr1-cell transcriptional network, the molecular cues that control the differentiation of Tr1 cells remain largely unknown (8, 9) . Seminal studies have demonstrated that aryl hydrocarbon receptor (AhR), along with the c-Maf proto-oncogene transcription factor (c-Maf), participate in human Tr1-cell generation; still, these transcription factors also contribute to the differentiation of other Th subsets, and thus cannot be considered as Tr1-cell lineage specification factors (8) (9) (10) .
Moreover, the precise molecular pathways underlying the suppressive functions of human Tr1 cells remain incompletely defined.
Activin-A is a member of the TGF-β superfamily, initially described as a gonadal protein stimulating the biosynthesis and secretion of follicle-stimulating hormone (11) . Since then, a growing body of evidence has uncovered critical functions for activin-A as a cytokine in fundamental biological processes, including development, hematopoiesis, tissue repair, stem cell maintenance, and differentiation (12) . In line with this evidence, mice lacking the βA subunit of activin-A die after birth due to severe craniofacial defects, whereas mice lacking the βB subunit exhibit abnormal development and reduced reproductive capacity (13, 14) . Activin-A signals through a heterotetrameric receptor complex consisting of two types of activin receptors: the type I activin-like kinase (ALK2, ALK4, and ALK7) receptors and the type II activin (ActRIIA and ActRIIB) receptors, which, upon activation, phosphorylate receptorregulated Smads (R-Smads) that translocate in the cell nucleus and regulate gene transcription (15) . Activin-A exerts both beneficial and detrimental effects on allergic inflammation and linked diseases, depending on the route of administration and the spatiotemporal context (16, 17) . Our previous studies, using an ovalbumin-induced mouse model of allergic airway inflammation, have revealed that activin-A protects against experimental asthma partly through the generation of Foxp3 − IL-10 + Treg cells (18) . Moreover, we and others have shown that activin-A and its signaling components are induced in T cells infiltrating the lungs of asthmatics and become further up-regulated following in vivo inhalational allergen challenge (19, 20) . Still, the effects of activin-A on the generation of human Treg cells suppressive against allergic responses, and the molecular mechanisms involved, remain unexplored.
Here, using an experimental approach that combines in vitro priming of human naive T cells with ex vivo analysis of T-effector cells, we demonstrate that activin-A instructs the differentiation of human IL-10-producing Tr1-like cells that inhibit allergen-induced T-cell responses. Mechanistic studies show that activin-A signaling induces the activation of IRF4 in human T cells, which binds in IL10 and ICOS promoter elements and controls gene expression. Moreover, our findings reveal that IRF4, along with AhR and its binding partner, AhR nuclear translocator (ARNT), form a transcription factor complex that is essential for effector molecule expression by human Tr1 cells. We further demonstrate that in vivo administration of human activin-A-induced Tr1-like (act-A-iTr1) cells can prevent, and even reverse, established allergic airway inflammation and confer protection against asthma manifestations in an IL-10-dependent manner. Collectively, our studies unravel activin-A as an inducer of human Tr1 cells that may be exploited for the suppression of allergic inflammation and the reestablishment of tolerance.
Results
Activin-A Drives the Differentiation of IL-10-Producing Human Tr1-Like Cells. To delineate the effects of activin-A on the regulation of human T-cell-driven allergic responses, we used our well-established in vitro T-cell priming model (21, 22) . Briefly, we sorted naive CD4 + T cells from the peripheral blood of atopic individuals and stimulated them with allergen-loaded, mitomycin-treated, CD3-depleted antigen-presenting cells (APCs) in the presence of activin-A or control (PBS) (Fig. S1 ). This protocol has been shown to skew T-cell responses toward Th2 (23 Fig. S2 A and B) . In contrast, activin-A-stimulated T cells displayed a reduced proliferative capacity and significantly decreased percentages of cytokine-producing cells ( Fig. 1 A and B and Fig. S2B ). Remarkably, activin-A significantly increased the frequencies of CD4 + IL-10 + T cells (Fig. 1A and Fig. S2B ). In accordance with the flow cytometry data, activin-A-treated human T cells expressed low levels of mRNAs encoding IL-4, IL-13, IL-5, IFN-γ, and IL-17, whereas IL-10 levels were increased (Fig. S2C) . Moreover, IL-4, IL-13, and IFN-γ release in culture supernatants was decreased, whereas IL-10 production was significantly elevated in the presence of activin-A (Fig. 1C) . Blockade of TGF-β in primary induction cultures did not affect the activin-A-mediated increase in the percentages of CD4 +
IL-10
+ T cells (Fig. S2D ). Interestingly, activin-A-treated T cells remained unresponsive upon secondary restimulation with fresh allergen-loaded APCs ( Fig. S3 A and B) . This hyporesponsiveness was not associated with induction of T-cell apoptosis/necrosis, as reflected by similar frequencies of 7AAD
+ T cells among activin-Aand control-treated T cells (Fig. S3C) . In fact, addition of IL-2 reversed activin-A antiproliferative effects, similar to recent observations on human follicular helper T (Tfh) cells (24) (Fig. S3D) . Notably, activin-A-treated CD4 + T cells exhibited Ag specificity because allergen-primed T cells retained their ability to respond upon subsequent exposure to tetanus toxoid, an irrelevant antigen (Fig. S3E) . Activin-A significantly decreased T-cell proliferation and enhanced the frequencies of CD4 +
+ T cells in the context of anti-CD3/CD28 stimulation in the absence of APCs, pointing to direct effects on CD4 + T cells that are not associated with regulation of APC functions ( Fig. S4 A and B) . Statistical significance was obtained by the Student's t test (*P < 0.05; **P < 0.01; ***P < 0.001).
To characterize the immunophenotype of activin-A-treated human T cells further, we investigated the expression of Treg-cellassociated markers. PD-1, GITR, and CTLA-4 were expressed at equivalent levels between activin-A-and control-treated T cells (Fig. S5 A and B) . Moreover, Foxp3 expression did not differ between the two groups ( Fig. S5 C and D) . Still, ICOS levels were markedly increased upon stimulation with activin-A, whereas the T-cell activation markers CD69, CD25, and CD127 were decreased ( Fig. S5 A and B) . CRTh2, CCR3, CCR4, CCR5, CCR6, and CXCR3 were dampened in activin-A-treated T cells, whereas CCR7 was increased ( Fig. S6 A and B) . Interestingly, we observed a striking increase in the percentages of ICOS + IL-10 + CD4 + T cells among activin-A-treated T cells, accompanied by markedly elevated IL10 and ICOS mRNA levels ( Fig. 1 D and E) . Moreover, a large proportion of CD4
+ T cells among activin-A-treated T cells expressed CD49b and LAG3, recently identified as human Tr1-cell-associated markers (25) , concomitant with a significant increase in the mRNAs encoding LAG3 and GZMB ( Fig. 1 E and F) .
IL-10-induced human Tr1 cells, generated as previously described (25) , contained similar percentages of CD4 +
+ T cells, compared with activin-A-treated CD4 + T cells, whereas LAG-3 and CD49b expression was increased in IL-10-induced Tr1 cells (Fig. S7 A and B) . The expansion of activin-A-treated CD4 + T cells in culture was significantly increased compared with the expansion of IL-10-induced Tr1 cells, which exhibited poor expansion in agreement with previous studies (25) (Fig. S7C) .
Notably, even after prolonged (4 wk) T-cell receptor stimulation, CD4
+ T cells stimulated with activin-A did not express Th-effector cytokines, although they maintained high frequencies of CD4 +
Collectively, these findings reveal that activin-A stimulation restrains allergen-driven human T-cell responses and instructs the differentiation of IL-10-producing Tr1-like cells. + T responders and allergen-primed APCs. Our data showed that activin-A-treated T cells greatly suppressed the proliferation of T responders, even at high T-responder/T-suppressor ratios ( Fig. 2 A and B) . Moreover, act-A-iTr1 cells significantly decreased IL-5 and IL-13 release in culture supernatants (Fig. 2C) . Still, IFN-γ levels remained unaltered, possibly due to activation of a counterbalancing mechanism used by act-A-iTr1 cells to inhibit Th2 cytokine secretion (Fig. S9A ). In contrast, control-treated T cells did not exhibit discernible suppressor functions ( Fig. 2 A-C). The proliferation of act-A-iTr1 cells remained low in suppressive cultures (Fig. 2B ). Naive T responders cultured with allergen-pulsed APCs alone displayed enhanced proliferative capacity, compared with the other groups (Fig. 2B ). IL-10-induced human Tr1 cells demonstrated an enhanced suppressive capacity toward T-responder cell proliferation, compared with act-A-iTr1 cells (Fig. S7D) .
To elucidate the mechanisms involved in the suppressive functions of human act-A-iTr1 cells, we initially used a transwell system. The suppressive capacity of activin-A-treated CD4 + T cells across a permeable membrane was decreased, but not abolished, in this setting, pointing to the involvement of both cell contact-dependent and independent mechanisms (Fig. 2D) . Indeed, transfer of the conditioned medium (CM) obtained from the supernatants of act-A-iTr1 cells to fresh CD4 + T-cell/APC cocultures suppressed T-responder proliferation (Fig. 2E) . Interestingly, IL-10 production was significantly increased in secondary cultures ( [H]Thymidine incorporation and IL-10 release are depicted. Data are expressed as mean ± SEM of triplicate wells and are pooled from n = 4-6 separate experiments (n = 4 donors). (F) CM from Tconv or act-AiTr1 culture supernatants was added to naive CD4 + T-cell/APC cocultures, as indicated. 3 [H]Thymidine incorporation is depicted, and data are expressed as mean ± SEM of triplicate wells and pooled from n = 3-4 experiments (n = 4 donors). Statistical analysis was performed by the Student's t test (A-C and E) and a nonparametric (Mann-Whitney) unpaired Student's t test (D and F) (*P < 0.05; **P < 0.01; ***P < 0.001).
activin-A did not significantly affect their functions (Fig. S9B) . Concomitant blocking of IL-10, TGF-β, and ICOS signaling further reduced act-A-iTr1 cell inhibitory functions, compared with blocking each pathway alone or combinations of two; however, the data did not reach statistical significance (Fig. S9B) . Overall, these findings reveal that human act-A-iTr1 cells exhibit robust suppressive functions against naive and effector T-cell responses to allergen through IL-10-, TGF-β-, and ICOS-dependent pathways.
IRF4 Is Activated in Human Act-A-iTr1 Cells and Forms Multipartite
Complexes with AhR in the ICOS Promoter. We next attempted to decipher the transcriptional pathways contributing to activin-A-induced human Tr1-cell differentiation. Investigation of the expression of the major Th-cell lineage-associated transcription factors TBX21, GATA3, and RORC at an earlier time point (day 3) during T-cell differentiation demonstrated that mRNA levels were similar or slightly decreased in act-A-iTr1 cells, whereas FOXP3 was moderately increased, compared with Tconv cells (Fig. 3A) . Interestingly, act-A-iTr1 cells expressed increased transcripts of the Tr1-cellassociated transcription factors MAF (encoding c-Maf) and AHR, along with its major gene target, xenobiotic metabolizing enzyme cytochrome P450, encoded by CYP1A1 (8) (Fig. 3A) . Moreover, activin-A stimulation induced a marked up-regulation in the mRNA levels of IRF4, a transcription factor not previously associated with human or mouse Tr1 cells (Fig. 3A) . Inhibition of activin-A signaling, using an anti-ALK4 antibody or the Smad3 inhibitor (SIS3), decreased activin-A-induced gene transcription, pointing to the involvement of its canonical signaling pathways (Fig. 3B ). Confocal microscopy studies demonstrated that activin-A stimulation induced an enhanced translocation of IRF4, c-Maf, and AhR into the nucleus of human CD4 + T cells (Fig. 3C) . Comparison of the global gene expression profile of human act-A-iTr1 cells with the global gene expression profile of Tconv cells, using RNA-sequencing (RNA-seq) analysis, revealed notable differences in their transcriptome profile, with 513 genes being significantly differentially regulated, 200 of which were down-regulated and 313 of which were up-regulated ( Fig. S10 A and B) . Volcano plot visualization demonstrated that the transcriptional signature of act-A-iTr1 cells was characterized by substantial changes compared with Tconv cells, with nearly 50% of the total differentially expressed genes showing a difference in expression greater than twofold [log 2 (fold change [FC]) < −1 or > 1] (Fig. S10A) . These genes belonged to biologically important gene families, including chemokines/cytokines or their receptors, transcription factors, surface receptors, and Treg-cell markers (Fig. S10B) . Interestingly, several genes, including LAG3, IRF4, GZMB, CCL1, CSF2, DGKI, CD70, and EBI3, were enriched in both human act-A-iTr1 cells and IL-10-induced Tr1 cells (25) , whereas others, such as CCL18, WNT2B, MMP15, and CD163, were downregulated in both groups (Fig. S10C) .
In view of the aforementioned findings, we hypothesized that activin-A up-regulates IL10 and ICOS expression in human CD4 + T cells through IRF4-, AhR-, and c-Maf-dependent pathways. To examine this hypothesis, we initially performed bioinformatics analysis to decipher whether these transcription factors have putative binding sites in human IL10 and ICOS gene loci. Indeed, we identified two IRF4-binding sites [IFN-stimulated response elements (ISREs)] in the IL10 promoter and three ISREs in the ICOS locus (Fig. 4 A and B) . In agreement with previous studies, we found a putative AhR-binding site [xenobiotic response element (XRE-1)] and a c-Maf site [MAF-recognition element (MARE-1)] within the IL10 promoter, which were in high proximity and partially overlapping (8) (Fig. 4A) . Moreover, we identified a c-Maf-binding site (MARE-2, −150 bp) in the IL10 promoter and two XRE and five MARE sites in the ICOS locus (Fig. 4 A and B) . We next focused on investigating whether activin-A signaling in CD4
+ T cells induces the binding of IRF4, AhR, and c-Maf to their response elements in IL10 and ICOS loci. Chromatin immunoprecipitation (ChIP) assays revealed a marked enrichment of IRF4 binding to the ISRE (−318 bp) site in the IL10 promoter in act-A-iTr1 cells, compared with Tconv cells (Fig. 4C) . In addition, AhR and c-Maf bound on the XRE-1 (−230 bp) and MARE-1 (−200 bp) sites, respectively, in the IL10 promoter in human act-A-iTr1 cells (Fig. 4C) . In contrast, AhR showed no discernible binding to the XRE-1 element in the IL10 promoter in Tconv cells, whereas c-Maf bound moderately to its MARE-1 site (Fig. 4C) . Pertinent to the ICOS locus, our data showed that IRF4 exhibited great enrichment to its ISRE (−1.3 kb) site, whereas AhR bound to its respective XRE site (−1,440 bp) in act-A-iTr1 cells (Fig. 4D) . Modest binding of c-Maf to the MARE site (−1,330 bp) in the ICOS locus was also observed (Fig. 4D) .
The ability of IRF4 and AhR to bind to the ICOS promoter in human T cells in response to activin-A stimulation, and the proximity of their binding sites, prompted us to explore whether they form transcriptional complexes at the ICOS locus. To address this issue, we performed sequential ChIP analysis of activin-A-or Tconv cells. Remarkably, our findings identified the presence of IRF4/AhR complexes in the ICOS promoter in act-A-iTr1 cells, but not in Tconv cells (Fig. 4E) .
To dissect the molecular interactions of IRF4 with AhR further, we performed in silico analysis of putative protein-protein interactions between the two transcription factors. Because a description of the solved structures of the full-length sequences of these transcription factors is currently lacking, reliable models were constructed and submitted for molecular docking. Interestingly, our studies revealed that IRF4 and AhR can form a tripartite molecular complex together with the AhR-binding partner, ARNT (26) (Fig. 4F) . This complex was highly stable thermodynamically because after the minimization of its energy, it was characterized by an energy value of −260685.0 KJ/mol. Moreover, this structure remained stable throughout the duration (10 ns) of the molecular dynamics simulation studies. Additionally, when this energetically minimized complex was superimposed with the initial docking output, the rmsd values between the carbon α-atoms were extremely low (Cα rmsd values at 0.52 Å). Together, this evidence supports the notion that the proposed docking result of IRF4/AhR is highly reliable and exhibits high thermodynamic stability.
These results collectively demonstrate that activin-A induces the activation of IRF4, AhR, and c-Maf in human CD4 + T cells, which bind in their response elements in IL-10 and ICOS promoters through the formation of multipartite transcriptional complexes.
IRF4 and AhR Signaling Is Essential for Activin-A-Induced Human Tr1-Cell Differentiation. To obtain functional evidence that IRF4 is involved in activin-A-mediated differentiation of human Tr1-like cells, we used IRF4-specific shRNA (shIRF4) to target IRF4 expression in T cells directly. Briefly, CD4
+ T cells transduced with lentiviral particles containing constructs of GFP-shRNA for IRF4 were sorted based on viability and GFP expression, and used in in vitro suppression assays. Indeed, knockdown of IRF4 decreased IRF4, ICOS, and IL10 mRNA levels in CD4 + T cells in response to activin-A (Fig. 5A) . The percentages of LAG-3
+

CD49b
+ T cells were also decreased, compared with sh-scrambled-treated, activin-A-stimulated T cells (Fig. S10D) . IRF4 silencing also compromised the suppressive functions of act-A-iTr1 cells and partly reversed their hypoproliferative state (Fig. 5B and Fig. S10E ).
Because IRF4 assembles into a complex with AhR in human T cells in response to activin-A, we next explored the role of AhR in activin-A-induced responses using CH-223191, a potent AhR antagonist (8) . Pharmacological blockade of AhR nearly abrogated activin-A-induced AhR activation, as shown by a marked down-regulation of CYP1A1 mRNA (Fig. 5C) . Interestingly, inhibition of AhR signaling partly reversed activin-A-induced In the 4ZPR structure, the ARNT chain is shown in blue, the AHR template chain is shown in light blue, and the DNA is shown in magenta. Statistical analysis was performed by a nonparametric (Mann-Whitney) unpaired Student's t test (*P < 0.05).
IL10, ICOS, and MAF up-regulation and significantly decreased the frequencies of CD4
+ ICOS + IL-10 + T cells (Fig. 5C ). In addition, disruption of AhR signaling impaired the suppressive capacities of act-A-iTr1 cells, accompanied by a significant reduction in IL-10 release (Fig. 5D) . In summary, these results provide compelling evidence that IRF4 and AhR are critically involved in activin-Ainduced differentiation of human Tr1-like cells.
In Vivo Administration of Human Act-A-iTr1 Cells Prevents the
Development of Allergic Airway Disease. Considering ongoing efforts to use adoptive Treg-cell transfers as a therapy for immunemediated human diseases, the issue of their in vivo stability is of critical clinical importance. To explore whether act-A-iTr1 cells can maintain their suppressive functions upon transfer in vivo, we used a well-established humanized mouse model of allergic airway inflammation (23, 27, 28) . Briefly, we transferred allergenprimed human act-A-iTr1 or Tconv cells, along with autologous APCs, into immunodeficient NOD-SCID mice and examined their responses upon immunization and aerosol challenge with allergen (Fig. S11A) . Indeed, human CD4 + T cells isolated from the lymph nodes (LNs) of NOD-SCID mice reconstituted with act-A-iTr1 cells were able to suppress the proliferation and Th2 cytokine release by cocultured naive T responders in ex vivo suppression assays (Fig. S11B) . In contrast, CD4
+ T cells obtained from the LNs of Tconv-cell-reconstituted mice did not exhibit discernible suppressor functions (Fig. S11B ). These data indicate that act-A-iTr1 cells can retain their potent inhibitory functions against other T-cell responses even following in vivo transfer into a highly inflammatory milieu.
Subsequently, we investigated whether in vivo administration of human act-A-iTr1 cells in a preventive protocol could confer protection against features of experimental asthma (Fig. S11C) . Indeed, adoptive transfer of act-A-iTr1 cells significantly decreased AHR to metacholine, a cardinal asthma manifestation, induced by cotransferred human T effectors (Fig. 6A) . Importantly, administration of act-A-iTr1 cells significantly dampened inflammatory cell influx in the bronchoalveolar lavage (BAL) and prevented the development of pulmonary inflammation (Fig. 6 B  and C) . Tconv cells did not suppress airway inflammation or AHR; in fact, allergic responses were enhanced compared with recipients of T responders alone (Fig. 6 A-C) . Considering the key role of IL-10 in the suppressive functions of human act-AiTr1 cells in vitro, we examined its effects in vivo through administration of an anti-IL-10R antibody (or an isotype-matched control) (Fig. S11C) . Disruption of IL-10 signaling partly reversed the suppressive effects of act-A-iTr1 cells on AHR and lung inflammation, but did not affect inflammatory cell responses in the BAL, compared with mice that received act-A-iTr1 cells but were treated with the isotype-matched control antibody (Fig. 6 A-C) .
To explore the effects of act-A-iTr1 cells on the regulation of human T-effector responses in vivo, we isolated lung-draining lymph node (DLN) cells and restimulated them with allergen ex vivo. In line with the attenuated allergic airway disease severity, the capacity of DLN cells to proliferate and secrete IL-13 was significantly decreased in mice cotransferred with act-AiTr1 cells, an effect that was partly reversed upon inhibition of IL-10 signaling (Fig. 6D) . Moreover, the frequencies of IL-4 + and IL-13 + CD4 + T-effector cells in the DLNs of mice administered act-A-iTr1 cells were significantly decreased, and this effect was also reversed upon IL-10R blockade (Fig. 6E) .
Altogether, these findings reveal that human act-A-iTr1 cells retain their immunosuppressive properties upon transfer in vivo and confer significant protection against asthma manifestations, partly through an IL-10-dependent mechanism.
Therapeutic Administration of Human Act-A-iTr1 Cells Reverses Established Allergic Responses and Ameliorates Asthma Severity.
To explore whether human act-A-iTr1 cells could reverse ongoing allergic airway inflammation, we adoptively transferred act-A-iTr1 cells, right before aerosol challenge, in mice reconstituted with T cells and sensitized to allergen (Fig. S11D) . Indeed, administration of act-A-iTr1 cells induced a significant [H]Thymidine incorporation and IL-10 release are shown. Data are mean± SEM of triplicate wells and are pooled from n = 4 independent experiments (n = 2 donors). Statistical significance was obtained by the Student's t test (*P < 0.05; **P < 0.01; ***P < 0.001).
decrease in AHR induced by human Th2-effector cells and attenuated inflammatory cell infiltration in the lungs (Fig. 7 A and  B) , suggesting that this regime may have applications in ameliorating disease manifestations.
Finally, to investigate whether our findings had potential clinical relevance, we examined the effects of activin-A on the suppression of T-cell responses to mixed grasses extract, a clinically relevant allergen, from individuals with atopy as well as distinct asthma severities. Interestingly, activin-A induced a significant decrease in robust proliferative responses of CD4 + T cells to allergen in atopic individuals and in subjects with mild/moderate and severe asthma (Fig. 7 C and  D and Fig. S12 A and B) . This decrease was accompanied by a substantial down-regulation in the release of IL-5 and IL-13 ( Fig. 7 C  and D and Fig. S12 A and B) . Notably, activin-A also restrained T-cell responses, including IL-17 production, in a small group of patients with severe, steroid-refractory asthma (Fig. S12 C and D) .
Discussion
In the present studies, we uncover activin-A as an inducer of human Tr1-like cells that exhibit highly suppressive functions against allergen-induced naive and effector Th2 responses. Moreover, our data underscore a crucial role for IRF4 in human Tr1 cell biology, showing that in response to activin-A, IRF4 assembles into a multipartite molecular complex with AhR and controls Tr1-cell differentiation and effector functions. Of translational importance, we demonstrate that upon therapeutic transfer in a humanized model of allergic asthma, act-A-iTr1 cells confer protection against cardinal disease manifestations. Overall, our studies highlight human act-A-iTr1 cells as potent therapeutic targets that can be used for the design of novel cell-based immunotherapies aiming to control allergic diseases.
Using our established in vitro human T-cell priming model that closely resembles the allergen sensitization phase, we demonstrated that activin-A significantly inhibits T-cell proliferation and Th2-effector cytokine release and renders human T cells hyporesponsive following reexposure to allergen in vitro and adoptive transfer into humanized mice in vivo. In addition, stimulation with activin-A endowed human naive T cells with key Tr1-cell-associated characteristics, such as expression of ICOS, LAG3, CD49b, and granzyme-B as well as production of copious amounts of IL-10 ( + Treg cells in mice (17, 24, 32) . Considering that several cytokines induce the differentiation of Th cells into distinct subsets depending on the context and the presence of other cytokines in the micromilieu (33), our findings demonstrating that activin-A can drive the differentiation of human Tr1-like cells extend the findings of previous reports.
An important finding of the present studies is the newly identified role of IRF4 as an essential component of the transcriptional network through which activin-A instructs human Tr1-cell differentiation. IRF4 contributes to the generation of several Th subsets, such as Th1, Th2, Th17, and T follicular helper cells; still, its involvement in human Tr1 cell biology has not been previously described (34, 35) . Our findings demonstrate that IRF4 knockdown impairs activin-A-induced IL10 and ICOS up-regulation, decreases the percentages of LAG3 representative of two to three independent experiments (n = 4-6 mice per group). Statistical analysis was performed by the Student's t test (*P < 0.05; **P < 0.01; ***P < 0.001).
and computational studies, we provide evidence that IRF4 forms a transcriptional complex with AhR and ARNT that seems to be important for activin-A-induced ICOS up-regulation in Tr1 cells.
Considering that AhR and ARNT activate target gene expression through direct interactions with other transcription factors (26) , our data illuminate IRF4 as a key partner in AhR/ARNTdriven ICOS regulation. Interestingly, ablation of a conditional IRF4 allele in mouse Foxp3 + Treg cells reduces ICOS, Gzmb, and IL-10 expression and decreases their inhibitory capacity upon adoptive transfer in vivo, also implicating IRF4 in ICOS regulation and Treg-cell functions (36) . Taken together, it becomes evident that IRF4 represents a central nodule of the transcriptional machinery that instructs effector molecule expression and suppressive functions in both Foxp3 + Treg and Foxp3 − Tr1 cells. Our results also showed that inhibition of AhR signaling abrogates activin-A-induced IL10 and ICOS up-regulation and impairs the inhibitory capacities of human act-A-iTr1 cells. Seminal studies have demonstrated that, depending on the stimuli, signaling through AhR drives the differentiation of human naive T cells into either Foxp3
+ Treg cells or Foxp3 − Tr1 cells (8, 9) . Our studies strengthen this notion, adding activin-A to the team of factors that use AhR-induced signals for the differentiation of human Tr1 cells. Moreover, because in the presence of TGF-β, AhR activation leads to the generation of Foxp3 + Treg cells, our findings reinforce the concept that although belonging to the same superfamily, activin-A and TGF-β exert disparate nonredundant functions on human T-cell responses, instructing the differentiation of distinct Treg-cell subsets (18) . In agreement, neutralization of TGF-β did not affect an activin-A-mediated increase in the percentages of CD4 + T cells, interactions between these transcription factors may also operate in our settings and will be investigated in future studies (9) .
A striking finding of our studies was that in vivo administration of act-A-iTr1 cells prevented the development of allergen-driven airway inflammation and ameliorated disease severity in a humanized model of allergic asthma. Of high relevance to clinical settings, we also showed that mice receiving act-A-iTr1 cells during allergen inhalational challenge and after the establishment of allergic inflammation exhibited dampened Th2-effector responses and attenuated pulmonary inflammation, suggesting that this regime may have therapeutic applications. Notably, the inhibitory functions of act-A-iTr1 cells largely depended on IL-10 signaling in vivo, further emphasizing the crucial role of IL-10 in the establishment of tolerance in the airway (4, 37) . In severe asthma, T-effector cells are overactivated and often become resistant to mainstay immunosuppressive therapies, including corticosteroids. Given that activin-A was able to restrain allergen-driven responses by T-effector cells from asthmatic individuals across the spectrum of disease severity, our studies may mark this cytokine as a potentially attractive therapeutic target for asthma.
In conclusion, we have identified an activin-A-induced, IRF4/ AhR-dependent transcriptional network that instructs the differentiation of human Tr1 cells suppressive against Th2-cellmediated allergic responses. Considering that adoptive T-cell therapies are underway to control immune-mediated diseases, our findings illuminate act-A-iTr1 cells as targets that can be exploited for the control of asthma and other human diseases associated with dysregulated immunity.
Materials and Methods
Study Population. Peripheral blood samples were obtained from 13 atopic individuals without asthma and 22 individuals with atopic asthma (mild/ moderate and severe) at the "Sotiria" Athens Chest Hospital, the Allergology Department of the General Military Hospital of Athens, and the Lugano and Milano University Hospitals. Asthma was defined according to the latest guidelines from the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma 2015 (ginasthma.org/2017-gina-reportglobal-strategy-for-asthma-management-and-prevention). Severe asthma was defined according to the latest American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (38) . Subjects did not receive treatment with anti-IgE or anti-IL-5 monoclonal antibodies throughout the study. Atopic and asthmatic individuals had a positive skin prick test result (wheal size ≥ 3 mm) to LPS-free mixed grasses extract, and/or increased allergen-specific IgE and blood samples were taken out of season. On entering the study, subjects were stable. Individuals with no clinical features of infection for at least 4 wk before the start of the study and none throughout the study period were included. Patients with autoimmune disorders, cancer, and/or other respiratory diseases were excluded. The study was conducted according to the principles described in the Declaration of Helsinki, and participants signed a written informed consent form before inclusion in the study approved by the ethics committee of "Sotiria" Neutralizing antibodies against activin-A (20 μg/mL; R&D Systems), IL-10R (30 μg/mL; R&D Systems), ICOS ligand (ICOSL) (25 μg/mL; eBioscience), and TGF-β (7.5 μg/mL; R&D Systems) were added in secondary suppressive cultures. In other experiments, Tconv, act-A-iTr1, or IL-10-Tr1 cells were cocultured with naive CFSE-labeled CD4 + T responders in the presence of anti-human CD3
(1 μg/mL) and soluble anti-human CD28 (1 μg/mL) for 5 d. The suppression of cell proliferation was calculated by measuring the proliferation [ Cytokine Analysis. Cytokines were measured in culture supernatants and mouse BAL using commercially available ELISA kits for human IL-10, IL-5, IL-4, IL-13, IL-17, and IFN-γ (R&D Systems).
Flow Cytometry Analysis. Cells were stained with fluorescently labeled antibodies to CD4, ICOS, PD-1, CTLA-4, GITR, CD25, CD69, CD127, LAG3, CD49b, CCR3, CCR5, and CRTH2 (all from eBiosciences); CCR4 (BD Pharmingen); and CCR6, CCR7, CXCR3, CD14, CD95, and CD45RA (all from Biolegend). The staining for CD49b and LAG3 was performed at 37°C for 20 min (25) . For intracellular cytokine staining, T cells were restimulated with phorbol 12-myristate 13-acetate (PMA)/ionomycin (Sigma-Aldrich) and Golgi-Stop (BD Biosciences), and stained with antibodies against IL-4, IL-5, and IL-13 (all from eBiosciences); IL-17 (Beckman Coulter); and IFN-γ (Beckman Coulter) according to the manufacturers' instructions. Foxp3 (eBiosciences) staining was performed according to the manufacturer's instructions. For IL-10 detection, T cells were restimulated with anti-CD3/CD28 antibodies overnight. FACS acquisition was performed with a Cytomics FC500 cytometer (Beckman Coulter) and an LSRFortessa cytometer (BD Biosciences), and data were analyzed using FlowJo software.
Immunofluorescence Microscopy. T-cell cytospins (5 × 10 4 cells per slide) were prepared in poly-L-lysine slides (Thermo Scientific), fixed in 4% (wt/vol) paraformaldehyde (at 4°C), and incubated in 10% sucrose. Slides were washed twice and blocked in 10% donkey serum, and then diluted in 0.1% Triton-X for 30 min. Slides were incubated overnight at 4°C with primary biotinylated antibodies against human AhR (Santa Cruz Biotechnology), c-Maf (Santa Cruz Biotechnology), IRF4 (R&D Systems), or control IgG (R&D Systems). Slides were then incubated with fluorescently labeled secondary antibodies (R&D Systems). Nuclear staining and mounting of the slides were carried out using ProLong Gold Anti-Fade Reagent with DAPI (Life Technologies). Image acquisition was performed by a confocal laser scanning microscope (Leica TCS SP5), and images were acquired by differential interference contrast optics. AhR Reconstitution of NOD-SCID Mice. In the prevention protocol, NOD-SCID mice were reconstituted on day 0 with 2 × 10 6 Tconv or act-A-iTr1 cells and 2 × 10 6 autologous APCs, and were immunized (i.p.) with Phleum pratense (5 μg per
